Autoimmune Disease Drugs
- Anti-Ulcerants
- Antibacterials
- Antibiotics
- Anticoagulants
- Antidiabetics
- Antifungals
- Antivirals
- Autoimmune Disease Drugs
- Biologics
- Biosimilars
- Cardiovascular Drugs
- Cellular Therapeutics
- Combination Therapies
- Dermatologic Drugs
- Enzyme Replacement Therapy
- Generics
- Hormone Replacement Therapy
- Immuno-oncology
- Immunotherapies
- Lipid Regulators
- Mental Health Drugs
- Oncologics
- Orphan Drugs
- Pain
- Protein Therapeutics
- Psychoactive Drugs
- Radiopharmaceuticals
- Respiratory Drugs
- Traditional Chinese Medications
- Vaccines
![GlaxoSmithKline (GSK) has made a $300 million equity investment in 23andMe under a collaboration designed to accelerate development of new therapies for both companies by using genetic data to identify new drug targets. [Source: © fotoliaxrender/Fotolia]](https://www.genengnews.com/wp-content/uploads/2018/08/Aug5_2014_56448122_DNAblue_NovelDiagnosticGenomic12114111424-265x198.jpg "GSK Invests $300M in 23andMe as Companies Collaborate on Drug Development")
